GlassScriptPhysician profile
Ilan J Danan
NPI 1831590439
$1,464.97
in general payments reported to CMS, 2019-2025
15 companies · $139 in 2025
The $139 reported for 2025 was less than what a typical Pain Medicine (Psychiatry & Neurology) provider received nationally (typical 2025 total: $405).
See the full distribution for Pain Medicine (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $644 · 2020: $32.07 · 2021: $175 · 2022: $27.99 · 2023: $185 · 2024: $262 · 2025: $139.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $586.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $586.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nevro Corp. | $448.20 | 2019-2021 | |
| Abbvie INC. | $313.05 | 2021-2025 | Botox, Qulipta, Ubrelvy |
| Spr Therapeutics, INC | $257.82 | 2021-2024 | Sprint Pns System |
| Lilly USA, LLC | $94.64 | 2019-2021 | |
| Assertio Therapeutics, INC. | $72.42 | 2019 | |
| Amgen INC. | $54.99 | 2019-2020 | |
| Pacira Pharmaceuticals Incorporated | $33.33 | 2021 | |
| Biodelivery Sciences International, INC. | $32.10 | 2019 | |
| Vertex Pharmaceuticals Incorporated | $31.99 | 2025 | |
| Teva Pharmaceuticals USA, INC. | $25.35 | 2019 | |
| Lundbeck LLC | $23.23 | 2025 | Vyepti |
| Medtronic USA, INC. | $22.34 | 2019 | |
| Collegium Pharmaceutical, INC. | $21.70 | 2025 | Belbuca |
| Avanir Pharmaceuticals, INC. | $17.18 | 2019 | |
| Allergan, INC. | $16.63 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ilan Danan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.